Lista de obras -

A novel platform for detection of CK+ and CK- CTCs

artículo científico publicado en 2011

Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis

artículo científico publicado en 2010

Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma

artículo científico publicado en 2006

Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.

artículo científico publicado en 2010

Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer

artículo científico publicado en 2010

Clinical and biological significance of tissue transglutaminase in ovarian carcinoma

artículo científico publicado en 2008

Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer

artículo científico publicado en 2009

Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma

artículo científico publicado en 2010

Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.

artículo científico publicado en 2015

EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer

artículo científico publicado en 2009

Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.

artículo científico publicado en 2006

HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma

artículo científico publicado en 2008

Impact of vessel maturation on antiangiogenic therapy in ovarian cancer

artículo científico publicado en 2008

Markers of angiogenesis in ovarian cancer

scientific article published on January 2007

Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute

artículo científico publicado en 2014

The dicey role of Dicer: implications for RNAi therapy

artículo científico publicado en 2010

Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer

artículo científico publicado en 2008

Lista de obras de

A novel platform for detection of CK+ and CK- CTCs

Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis

Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma

Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.

Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer

Clinical and biological significance of tissue transglutaminase in ovarian carcinoma

Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer

Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma

Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.

EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer

Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.

HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma

Impact of vessel maturation on antiangiogenic therapy in ovarian cancer

Markers of angiogenesis in ovarian cancer

Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute

The dicey role of Dicer: implications for RNAi therapy

Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer